Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | IDH2 | P48735 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19784023 | 1.00 | PDE4A (0.42) | PDE4AKCNH2KMT2AMEN1LMNA | |
| SCHEMBL19783912 | 0.92 | PDE4A (0.42) | PDE4AKCNH2KMT2AMEN1LMNA | |
| SCHEMBL19783910 | 0.92 | PDE4A (0.42) | PDE4AKCNH2KMT2AMEN1LMNA | |
| SCHEMBL20532153 | 0.88 | KMT2A (0.38) | PDE4AKCNH2KMT2AMEN1LMNA | |
| SCHEMBL18312636 | 0.88 | KMT2A (0.38) | PDE4AKCNH2KMT2AMEN1LMNA | |
| SCHEMBL19783903 | 0.86 | GSK3B (0.35) | PDE4AKCNH2KMT2AMEN1LMNA | |
| SCHEMBL19783905 | 0.86 | GSK3B (0.35) | PDE4AKCNH2KMT2AMEN1LMNA | |
| SCHEMBL18313036 | 0.84 | KMT2A (0.39) | PDE4AKCNH2KMT2AMEN1LMNA | |
| SCHEMBL20531719 | 0.84 | KMT2A (0.39) | PDE4AKCNH2KMT2AMEN1LMNA | |
| SCHEMBL18313331 | 0.84 | KMT2A (0.39) | PDE4AKCNH2KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481823-B1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | US | disclosed |
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | US | disclosed |
| WO-2018011017-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | GLS, TNNI3, AADAC | PDE4A 793/4885KCNH2 1611/4885KMT2A 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.